Information about Actos and bladder cancer.

Actos manufacturers lose bid to overturn $9B punitive damages award

September 19th, 2014

Actos manufacturer Takeda Pharmaceuticals and its U.S. partner Eli Lilly & Co. lost a bid to have a judge overturn a $9 billion punitive damages award given in a recent Actos lawsuit. The judge ruled that the jury properly considered evidence showing that Takeda and Eli Lilly knew Actos caused bladder cancer but failed to warn patients and doctors.

The $9 billion punitive damages award is the second-largest in the U.S. and is intended to deter companies from wrongdoing. The companies were also ordered to pay Terrence Allen $1.5 million in compensatory damages for the hospital bills and missed work related to his Actos bladder cancer.

Actos, which accounts for as much as 27% of Takeda’s revenue, is a type 2 diabetes drug that has been directly linked to an increased risk of bladder cancer in patients who use the drug for at least one year. Takeda faces multiple Actos lawsuits alleging that the company failed to properly warn doctors and patients of the increased risks of bladder cancer associated with Actos.

Contact Us Today for a Free Consultation.

I am currently represented by an attorney.
*Required fields